公开(公告)号：US20240309011A1

公开(公告)日：2024-09-19

申请号：US18423156

申请日：2024-01-25

申请人： Cytokinetics, Inc.

发明人： Bradley P. MORGAN ,  Chihyuan CHUANG ,  Luke W. ASHCRAFT ,  Justin HO ,  Alfredo GARCIA

IPC分类号： C07D487/10 ,  A61P9/04

CPC分类号： C07D487/10 ,  A61P9/04

摘要： Provided are compounds of Formula (I):




or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R1, R2, R3, and R4 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of using a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

公开(公告)号：US20240101517A1

公开(公告)日：2024-03-28

申请号：US18520156

申请日：2023-11-27

申请人： Cytokinetics, Inc.

发明人： Sheng CUI ,  Henry MORRISON ,  Karthik NAGAPUDI ,  Shawn D. WALKER ,  Charles BERNARD ,  Karl Bennett HANSEN ,  Neil Fred LANGILLE ,  Alan Martin ALLGEIER ,  Steven MENNEN ,  Jacqueline C.S. WOO ,  Bradley Paul MORGAN ,  Alex MUCI (DECEASED)

IPC分类号： C07D213/75 ,  A61K9/20 ,  A61K31/496 ,  A61K47/38

CPC分类号： C07D213/75 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/496 ,  A61K47/38

摘要： Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US20240067631A1

公开(公告)日：2024-02-29

申请号：US18268569

申请日：2021-12-20

申请人： Cytokinetics, Inc.

发明人： Minxing SHEN ,  Antonio ROMERO ,  Pu-Ping LU

IPC分类号： C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

CPC分类号： C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

摘要： Provided herein are compounds of formula (A): or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, Ry, and Rz are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (A), or a pharmaceutically acceptable salt thereof, as well as methods of using a compound of formula (A), or a pharmaceutically acceptable salt thereof, to treat various diseases and conditions mediated by nicotinamide phosphoribosyltransferase (NAMPT).

公开(公告)号：US20230149394A1

公开(公告)日：2023-05-18

申请号：US18155483

申请日：2023-01-17

申请人： Amgen Inc. ,  Cytokinetics, Inc.

发明人： Narimon HONARPOUR ,  Fady Malik

IPC分类号： A61K31/496 ,  A61P9/04 ,  A61K9/00

CPC分类号： A61K31/496 ,  A61P9/04 ,  A61K9/0053

摘要： Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.

公开(公告)号：US20230119665A1

公开(公告)日：2023-04-20

申请号：US17823910

申请日：2022-08-31

申请人： Cytokinetics, Inc.

发明人： Chihyuan CHUANG ,  Bradley P. MORGAN ,  Mark VANDERWAL ,  Wenyue WANG ,  Luke W. ASHCRAFT

IPC分类号： C07D413/12 ,  C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  A61P9/04 ,  A61P9/00 ,  C07D403/12 ,  C07D401/12 ,  C07D231/14 ,  C07D413/04 ,  C07D417/12 ,  C07F5/02

摘要： Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein.
Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230044617A1

公开(公告)日：2023-02-09

申请号：US17930695

申请日：2022-09-08

申请人： Cytokinetics, Inc.

发明人： Sheng CUI ,  Henry MORRISON ,  Karthik NAGAPUDI ,  Shawn D. WALKER ,  Charles BERNARD ,  Karl Bennett HANSEN ,  Neil Fred LANGILLE ,  Alan Martin ALLGEIER ,  Steven MENNEN ,  Jacqueline C.S. WOO ,  Bradley Paul MORGAN ,  Alex MUCI

IPC分类号： C07D213/75 ,  A61K9/20 ,  A61K31/496 ,  A61K47/38

摘要： Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

公开(公告)号：US11414424B2

公开(公告)日：2022-08-16

申请号：US16557281

申请日：2019-08-30

申请人： Cytokinetics, Inc.

发明人： Chihyuan Chuang ,  Bradley P. Morgan ,  Mark Vanderwal ,  Luke W. Ashcraft ,  Kevin Lau

IPC分类号： C07D487/10 ,  A61P9/04 ,  C07D241/08 ,  C07D241/38 ,  C07D401/04 ,  C07D401/06 ,  C07D401/08 ,  C07D403/08 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/08 ,  C07D413/14 ,  C07D417/08 ,  C07D491/107

摘要： Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11384053B2

公开(公告)日：2022-07-12

申请号：US16579360

申请日：2019-09-23

申请人： Cytokinetics, Inc.

发明人： Mingda Bi ,  Robert Kuehl

IPC分类号： C07D213/75 ,  A61K9/20 ,  A61K31/496 ,  A61K47/38

摘要： Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.

公开(公告)号：US20220185790A1

公开(公告)日：2022-06-16

申请号：US17593110

申请日：2020-03-12

申请人： Amgen Inc. ,  Cytokinetics, Inc.

发明人： Stephanie AZALI ,  Mary CHAVES ,  Ron C. KELLY ,  Steven M. MENNEN ,  Darren L. REID ,  Osama SULEIMAN ,  Ashraf WILSILY ,  Mark WRIGHT

IPC分类号： C07D401/06

摘要： Provided herein are free base crystalline forms, crystalline salts, solvates, amorphous free base, and cocrystals of Compound A.

公开(公告)号：US20210253563A1

公开(公告)日：2021-08-19

申请号：US17255336

申请日：2019-06-25

申请人： Cytokinetics, Inc.

发明人： Bradley P. MORGAN ,  Chihyuan CHUANG

IPC分类号： C07D413/12 ,  A61P9/04 ,  C07D498/10 ,  C07D413/04

摘要： Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, and R3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.